Figure 2.
Screening results. (A) Schematic of primary screening assay using MDCK cells expressing HRP-ΔF508-NBD1. Small molecules that correct the folding defect and/or stabilize ΔF508-NBD1 will increase the ΔF508-NBD1 cell surface expression as read out by the increased HRP luminescence signal. (B) Summary of primary screen showing data for all compounds, with cells expressing HRP-wild-type-NBD1 as the positive control. (C) Chemical structures of active compounds identified from the screen.